Oscity BioSciences buys Enantia cannabinoid cocrystal patents

Oscity BioSciences has acquired U.S. patents for cannabinoid cocrystal technology from Enantia to expand its production capabilities and push further into pharmaceutical development. The deal also sets up future research cooperation on higher-purity cannabinoid solid forms and potential API candidates.

Why it matters: - The patent deal gives Oscity BioSciences more control over cannabinoid purification and solid-form development. - The technology could support pharmaceutical-grade active ingredients with improved stability, consistency, and potential solubility. - The acquisition also positions Oscity to pursue higher-value applications beyond extraction and refinement.

What happened: - Oscity BioSciences acquired foundational U.S. patents covering cannabinoid cocrystal technology from Enantia, S.L.U. - The companies said the transaction opens the door to future scientific cooperation on research, development, and potential pharmaceutical applications. - The announcement was made Sept. 30, 2026. - Oscity is based in Foley, Alabama. - Enantia is based in Barcelona.

The details: - The acquired patents are U.S. Patent Nos. 11,168,047 and 11,993,563. - The patents cover cocrystals of cannabinoids, including cannabidiol, with selected coformers. - The intellectual property also covers processes for preparation and purification, plus solid compositions. - The technologies allow efficient cannabinoid purification without traditional chromatography. - The solid forms are designed to deliver higher melting points, greater consistency, enhanced stability, and potentially better solubility and bioavailability. - Oscity will use the patents alongside its cGMP-certified manufacturing capabilities in Foley, Alabama. - Enantia brings expertise in solid-form screening, process chemistry, and crystalline engineering. - Oscity plans to explore uses ranging from high-purity API production to potential clinical-stage medication candidates with pharmaceutical industry partners. - The companies said they will jointly pursue further research and development of cannabinoid cocrystals.

Between the lines: - The deal shows Oscity is trying to pair proprietary process technology with intellectual property to move deeper into pharmaceutical development. - The collaboration suggests both companies see commercial value in cannabinoid solid forms that can be standardized for drug development. - For Enantia, the transfer extends its pharmaceutical solid-state work into a new cannabinoid-focused area.

What's next: - Oscity and Enantia plan to continue research on cannabinoid cocrystal technology. - The companies may develop next-generation pharmaceutical-grade solid forms and API candidates. - Oscity intends to build on the patent portfolio as it works with potential partners on clinical-stage and commercial opportunities. - More information is available in Oscity BioSciences' announcement.